MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and fiscal year-end financial results before the markets open on Friday, March 7, 2025.
Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following:
| Toll free (U.S.) | 1-833-316-0561 |
| International (U.S) | 1-412-317-0690 |
| Germany | 0800-6647650 |
| Israel | 1-80-9212373 |
| Access Code | Please reference the “Lifeward Earnings Call” |
The conference call will be webcast live and the webcast can be accessed through a link on the Company’s website at GoLifeward.com in the "Investors" section, or through the following link: https://edge.media-server.com/mmc/p/9u4xjdep. An archived webcast will also be available on the company's website.
About Lifeward
Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity system, the ReStore Exo-Suit, and the MyoCycle FES System.
Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com.
Lifeward®, ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.
Lifeward Media Relations:
Kathleen O’Donnell
VP Marketing & New Business Development
Lifeward Ltd.
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
Lifeward Investor Contact:
Mike Lawless
Chief Financial Officer
Lifeward Ltd.
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.60 |
| Daily Change: | 0.09 5.96 |
| Daily Volume: | 456,872 |
| Market Cap: | US$17.010M |
March 13, 2025 March 06, 2025 February 19, 2025 February 05, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
